All In Biotech

Drug Trial Radar · NCT07391215

5G-PEARL: Paxalisib in Malignant Brain Tumours

5G-PEARL: Paxalisib in Combination With Temozolomide in Patients With High Grade Malignant Brain Tumours Within the 5G Platform

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Jan 19, 2026

Primary completion

Jan 19, 2029

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Institute of Cancer Research, United KingdomAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Minderoo Foundation; Kazia Therapeutics Limited; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cancer Research UK
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the safety and tolerability of paxalisib in combination with temozolomide and to determine the preliminary antitumour activity of the combination therapy. In the Phase 1b of this study parallel biomarker defined arms will be opened in the front-line unmethylated MGMT setting, enrolling 10 patients onto each arm. These patients will be treated with paxalisib in combination with temozolomide (TMZ). The starting dose of paxalisib will be 45mg once a day (OD) with the option of increasing to 60 mg (30 mg BD) in Cycle 2. TMZ will be administered once daily by mouth on days 1 to 5 in a 28-day cycle, with a starting dose of 150mg/m2 during cycles 1 and 2, and subsequent dose escalation to 200mg/m2 at the start of cycle 3 if cycles 1 and 2 have been well tolerated with no significant toxicity.

Conditions

  • Malignant Primary Gliomas
  • Glioblastoma Multiforme (GBM)

Interventions

  • PaxalisibDrug

    Supplied as 15 mg capsules (35 capsules per bottle).

  • Temozolomide capsuleDrug

    Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b - Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) in patients with malignant brain tumoursTime frame: 12 months
  2. Phase 1b - To determine the preliminary antitumour activity of the investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 12 months
  3. Phase 2 - To determine the antitumour activity of investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 24 months
  4. Phase 2 - To determine the antitumour activity of investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumoursTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Royal Marden NHS Foundation Trust

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.